OrganiGram Stock Outperforms the Broader Market, What Next?

OrganiGram stock

OrganiGram stock is one of the notable outperformers in the cannabis sector amid growing optimism.

OrganiGram Holdings (TSXV:OGI) (NASDAQ:OGI) has been one of the more interesting companies in the cannabis space for quite some time, and in a new development, the Canadian company became one of the chosen ones to partner with vaporizer company Pax Era.

The announcement was made last week, and it is a significant one for OrganiGram. Only four companies were chosen to supply cannabis products that would be suitable for the Pax ERA oil vaporizer.

Key Drivers

OrganiGram Holdings may have been slow to get off the blocks as far as a listing on a US stock exchange was concerned, and having only listed in May, it is perhaps a big boost for the company to have announced such a deal in June. Although the deal with Pax Era should not be the sole reason for keeping an eye on OrganiGram stock; there are other compelling reasons too.

One of the most important attributes that will be of interest to many investors is the fact that the company’s costs of production are among the lowest in the industry. That, in turn, allows OrganiGram to have a far bigger margin than many of its competitors.

Capitalize off Cannabis
Sign up now to start receiving our investing insights for FREE!


OrganiGram stock is trading lower by 4% at 6.53 on the Nasdaq.

>> Auxly Stock: Short Term Pain, but Long Term Gain?

Production Capabilities

In addition to that, the company’s production capabilities are going to increase in the near future as well. Currently, its output is pegged at 47,000 kilos a year, but the company has projected that the annualized production by the end of 2019 is going to hit 113,000 kilos. In the cannabis industry, production capacity is a major factor for continued growth, and in that regard, OrganiGram Holdings is not doing too badly.

OrganiGram has also signed supply agreements with as many as 10 provinces in Canada, and that is a significant achievement considering the fact that only three other cannabis companies have been able to achieve that.

It is also beefing up its capabilities in cannabis edibles and derivatives products, which are set to be quite popular in the near future. Last, but not least, the company has also forayed into the international market with two important deals.

OrganiGram has joined hands with Alpha Cannabis to gain a foothold in the thriving German medical cannabis industry, while an offtake understanding with Serbian hemp producer Eviana also looks promising. The deal with Eviana could open up the whole of Europe for OrganiGram Holdings when it wishes to supply hemp-based CBD products.

OrganiGram stock has rocketed 55% so far in 2019.

>> Read More OrganiGram News

Featured image: Canva

Please See Disclaimer


1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on my research and understanding of the sector.

2) The Article was issued on behalf of a third party, Organigram Holdings Inc. Market Jar Media Inc. has or expects to receive one hundred and forty-five thousand five hundred Canadian dollars from Organigram Holdings Inc.’s agency of record Native Ads Inc. for 14 campaign days (10 business days).

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here.. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.